tradingkey.logo

tradingkey.logo
怜玢


Valneva SE

VALN
りォッチリストに远加
4.970USD
-0.120-2.36%
終倀 07-31 16:00ET15分遅れの株䟡
469.87M時䟡総額
損倱額盎近12ヶ月PER

詳现情報 Valneva SE 䌁業名

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Valneva SEの䌁業情報


䌁業コヌドVALN
䌚瀟名Valneva SE
䞊堎日Jun 28, 2007
最高経営責任者「CEO」Lingelbach (Thomas)
埓業員数- -
蚌刞皮類Depository Receipt
決算期末Jun 28
本瀟所圚地6, Rue Alain Bombard
郜垂SAINT-HERBLAIN
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜France
郵䟿番号44800
電話番号33228073710
りェブサむトhttps://valneva.com/
䌁業コヌドVALN
䞊堎日Jun 28, 2007
最高経営責任者「CEO」Lingelbach (Thomas)

Valneva SEの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Director, Representative of Bpifrance Participations SA
Director, Representative of Bpifrance Participations SA
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--

よくある質問

Valneva SEの䞊䜍5名の株䞻は誰ですか


Valneva SEの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Franck Grimaud

Valneva SEVALNの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Valneva SEの株匏を保有しおいる機関は36瀟あり、保有株匏の総垂堎䟡倀は玄5.21Mで、党䜓の5.50%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-309162.00増加しおいたす。

Valneva SEの最倧の収益源は䜕ですか


2026Q1においお、IXIARO郚門がValneva SEにずっお最倧の収益を生み出しおおり、その金額は98.42Mで、党収益の56.35%を占めおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。